Article citationsMore>>

Navab, M., Berliner, J.A., Watson, A.D., Hama, S.Y., Territo, M.C., Lusis, A.J., Shih, D.M,, Van Lenten, B.J., Frank, J.S., Demer, L.L., Edwards, P.A. and Fogelman, A.M. (1996) The Yin and Yang of oxidation in the de- velopment of the fatty streak. A review based on the 1994 George Lyman Duff Me-morial Lecture. Arterioscler Thrombosis and Vascular Biology, 16, 831-842. doi:10.1161/01.ATV.16.7.831

has been cited by the following article:

• TITLE: Paraoxonase 1 gene (Gln192-Arg) polymorphism and the risk of coronary artery disease in type 2 diabetes mellitus

  AUTHORS: Mohamed Fahmy Elnoamany, Ashraf Abdelraouf Dawood, Rania Mohamed Azmy, Mostafa Mohamed Elnajjar

  KEYWORDS: Paraoxonase 1; Coronary Artery Disease; Diabetes Mellitus.

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.2 No.1, December 31, 2011

  ABSTRACT: Background: Paraoxonase 1 (PON1) is reported to have an antioxidant and cardioprotective properties. Recently, an association of glutamine (Gln) or (type A)/arginine (Arg) or (type B) polymorphism at position 192 of PON1 gene has been suggested with coronary artery disease (CAD) among patients with diabetes mellitus (DM). However, conflicting results have also been reported. Objectives: To investigate the relationship between PON1 gene (Gln192-Arg) poly-morphism and the presence, extent and severity of CAD in type 2 DM. Methods: The study comprised 180 patients recruited from those undergoing coronary angiography for suspected CAD, who were divided according to the presence or absence of CAD and DM into 4 groups; Group I (n = 40 patients) nondiabetic subjects without CAD, Group II (n = 45 patients) diabetic patients without CAD, Group III (n = 47 patients) non diabetic patients with CAD and Group IV (n = 48 patients) diabetic patients with CAD. PON1 (Gln192-Arg) genotype was assessed using polymerase chain reaction (PCR) followed by AlwI digestion. Results: The frequency of Gln allele (Type A) was significantly higher in group I and group II compared to group III and group IV (62.5%, 60% vs 38.3%, 31.25% respectively, p 100 mg/dL [OR 4.31, CI (1.25 - 12.5), P